Halter Ferguson Financial Inc. Buys New Shares in Eli Lilly and Company (NYSE:LLY)

Halter Ferguson Financial Inc. purchased a new position in shares of Eli Lilly and Company (NYSE:LLY) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 12,057 shares of the company’s stock, valued at approximately $7,028,000. Eli Lilly and Company accounts for approximately 4.5% of Halter Ferguson Financial Inc.’s investment portfolio, making the stock its 5th largest position.

A number of other institutional investors also recently made changes to their positions in LLY. Buckhead Capital Management LLC grew its stake in shares of Eli Lilly and Company by 0.7% in the fourth quarter. Buckhead Capital Management LLC now owns 2,104 shares of the company’s stock worth $1,226,000 after purchasing an additional 15 shares during the last quarter. Levin Capital Strategies L.P. increased its stake in Eli Lilly and Company by 3.8% in the 4th quarter. Levin Capital Strategies L.P. now owns 415 shares of the company’s stock valued at $242,000 after buying an additional 15 shares during the last quarter. Clearwater Capital Advisors LLC grew its position in shares of Eli Lilly and Company by 1.3% during the 4th quarter. Clearwater Capital Advisors LLC now owns 1,202 shares of the company’s stock valued at $701,000 after acquiring an additional 15 shares during the period. JGP Wealth Management LLC grew its position in shares of Eli Lilly and Company by 0.9% during the 4th quarter. JGP Wealth Management LLC now owns 1,843 shares of the company’s stock valued at $1,074,000 after acquiring an additional 16 shares during the period. Finally, Valley Wealth Managers Inc. grew its position in shares of Eli Lilly and Company by 1.3% during the 3rd quarter. Valley Wealth Managers Inc. now owns 1,280 shares of the company’s stock valued at $688,000 after acquiring an additional 17 shares during the period. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Trading Down 0.1 %

Shares of Eli Lilly and Company stock traded down $1.02 during trading on Friday, hitting $807.43. The stock had a trading volume of 1,758,200 shares, compared to its average volume of 2,993,735. The firm’s fifty day simple moving average is $764.43 and its 200-day simple moving average is $690.85. The stock has a market cap of $767.39 billion, a PE ratio of 119.20, a PEG ratio of 1.75 and a beta of 0.37. The company has a debt-to-equity ratio of 1.90, a current ratio of 1.35 and a quick ratio of 1.03. Eli Lilly and Company has a 12 month low of $419.80 and a 12 month high of $820.60.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Monday, May 6th. The company reported $2.58 EPS for the quarter, beating the consensus estimate of $2.53 by $0.05. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The business had revenue of $8.77 billion during the quarter, compared to analyst estimates of $8.94 billion. During the same quarter in the previous year, the business posted $1.62 EPS. The company’s quarterly revenue was up 26.0% compared to the same quarter last year. As a group, sell-side analysts expect that Eli Lilly and Company will post 13.78 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, June 10th. Stockholders of record on Thursday, May 16th will be issued a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 0.64%. The ex-dividend date of this dividend is Wednesday, May 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 76.58%.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on LLY shares. The Goldman Sachs Group boosted their price target on shares of Eli Lilly and Company from $650.00 to $723.00 and gave the company a “neutral” rating in a research report on Thursday, April 11th. DZ Bank cut shares of Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price target on the stock. in a research report on Wednesday, February 21st. Argus upped their price objective on shares of Eli Lilly and Company from $770.00 to $840.00 and gave the stock a “buy” rating in a report on Tuesday, May 14th. JPMorgan Chase & Co. increased their price objective on shares of Eli Lilly and Company from $850.00 to $900.00 and gave the company an “overweight” rating in a research report on Wednesday, May 1st. Finally, Erste Group Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Wednesday, April 3rd. Three investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $769.53.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.